Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Drops Numbers from New Mid-Term Plan; CEO Wants Value-Based Pricing for AD Meds
March 29, 2021
- Myrbetriq Earns US Approval for Pediatric NDO: Astellas
March 29, 2021
- AZ, Fujifilm to Codevelop Case Search System for Lung Cancer Patients Undergoing Chemoradiotherapy
March 29, 2021
- Ono Takes Part in University of California Drug Discovery Consortium
March 29, 2021
- Takeda Files Dengue Vaccine Candidate in Europe
March 29, 2021
- EMA Accepts Regulatory Filing of Enfortumab Vedotin: Astellas/Seagen
March 29, 2021
- Astellas Sees Growth Potential for “Rx+” as Future Bread-and-Butter Biz: EVP
March 26, 2021
- Boehringer’s Japan Sales Up 5.4% in 2020 as Ofev, Jardiance Fare Well
March 25, 2021
- Kissei Launches PIII Study of Oncolytic Viral Therapy for Bladder Cancer in Japan
March 25, 2021
- Chugai Earns Japan Nod for Blood-Based Genomic Profiling Test
March 24, 2021
- Sumitomo Dainippon Aims to Overcome Latuda Patent Cliff with Sumitovant Products: CSO
March 24, 2021
- Rohto Acquires Olympus’ Regenerative Medicine Unit
March 24, 2021
- Kowa, Kitasato Institute Team Up for Research of Infectious Disease Meds; Cepharanthine for COVID-19
March 24, 2021
- Shionogi Partner BioAge Begins US PII Study for COVID-19 Drug
March 24, 2021
- Taiho Files Antiemetic Fosnetupitant for Japan Approval
March 24, 2021
- Taisho Seeks Japan Approval for Anti-TNFα Nanobody Ozoralizumab
March 23, 2021
- Otsuka Files Tolvaptan Prodrug OPC-61815 in Japan
March 23, 2021
- Daiichi Sankyo Begins Japan PI/II for mRNA COVID-19 Vaccine
March 23, 2021
- KM Biologics Kicks Off Japan PI/II for COVID-19 Vaccine
March 23, 2021
- Eisai Starts Construction of New Injectable/Research Building in Gifu Pref.
March 23, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…